These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 32619168)

  • 1. Nanomedicine in Pancreatic Cancer: A New Hope for Treatment.
    Redruello P; Perazzoli G; Cepero A; Quiñonero F; Mesas C; Doello K; Láinez-Ramos-Bossini A; Rivera-Izquierdo M; Melguizo C; Prados J
    Curr Drug Targets; 2020; 21(15):1580-1592. PubMed ID: 32619168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclopamine treatment disrupts extracellular matrix and alleviates solid stress to improve nanomedicine delivery for pancreatic cancer.
    Zhang B; Wang H; Jiang T; Jin K; Luo Z; Shi W; Mei H; Wang H; Hu Y; Pang Z; Jiang X
    J Drug Target; 2018 Dec; 26(10):913-919. PubMed ID: 29533111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response.
    Lim CY; Chang JH; Lee WS; Lee KM; Yoon YC; Kim J; Park IY
    Pancreatology; 2018 Dec; 18(8):913-927. PubMed ID: 30292644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.
    Adiseshaiah PP; Crist RM; Hook SS; McNeil SE
    Nat Rev Clin Oncol; 2016 Dec; 13(12):750-765. PubMed ID: 27531700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer.
    Lu T; Prakash J
    Int J Nanomedicine; 2021; 16():6313-6328. PubMed ID: 34552327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
    Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
    Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer.
    Meng H; Nel AE
    Adv Drug Deliv Rev; 2018 May; 130():50-57. PubMed ID: 29958925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Emerging Landscapes to Drug Delivery Systems for the Treatment of Pancreatic Cancer.
    Magri A; Baveloni FG; de Camargo BAF; Chorilli M
    Curr Med Chem; 2021; 28(26):5411-5430. PubMed ID: 33745422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical models of pancreatic ductal adenocarcinoma.
    Hwang CI; Boj SF; Clevers H; Tuveson DA
    J Pathol; 2016 Jan; 238(2):197-204. PubMed ID: 26419819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Pancreatic Ductal Adenocarcinoma (PDAC).
    Parrasia S; Zoratti M; Szabò I; Biasutto L
    Cell Physiol Biochem; 2021 Jan; 55(1):61-90. PubMed ID: 33508184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
    García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
    Al Haddad AH; Adrian TE
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
    Lemstrova R; Melichar B; Mohelnikova-Duchonova B
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1101-1111. PubMed ID: 27250969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma.
    Engelhardt K; Riley C; Cooke L; Mahadevan D
    Curr Drug Discov Technol; 2006 Dec; 3(4):231-43. PubMed ID: 17430101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix control of pancreatic cancer: New insights into fibronectin signaling.
    Topalovski M; Brekken RA
    Cancer Lett; 2016 Oct; 381(1):252-8. PubMed ID: 26742464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal biology and therapy in pancreatic cancer.
    Neesse A; Michl P; Frese KK; Feig C; Cook N; Jacobetz MA; Lolkema MP; Buchholz M; Olive KP; Gress TM; Tuveson DA
    Gut; 2011 Jun; 60(6):861-8. PubMed ID: 20966025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
    Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.